Plant-based innovations
for human and animal health
Discover Serendip’s VLP technology
In close licensing partnership with our collaborators, we are committed to the success of their drug development programs by harnessing cutting-edge plant-based technology and natural bioreactors.
By enhancing stability, enabling targeted delivery, and ensuring efficient bioproduction, we help maximize the activity, safety, and economic viability of their drug candidates.
EFFICACY
Optimized half-life
Drug protection
Optimized activity
Drug concentration and specific delivery
Preventive immunization
B-cell response (against specific virus or bacteria)
Therapeutic immunization
Unique VLP for T-cell response (against specific tumor)
SAFETY
Reduced toxicity
Low dose concentration,
no off-target effect,
low reactogenicity
Human pathogen-free
No human pathogens are
introduced in the
plant-based bioreactors
Diluted impurities
Efficacy of the product at
low dose concentration,
so dilution is possible
Biocompatibility
The particle (VLP) is made
of degradable proteins
COST-EFFECTIVENESS
Fast-to-test
Quick screening method
(up to 8 weeks from ideation)
Based on different VLPs, codon optimization, protein design optimization, etc.
Fast-to-develop and produce
Bioprocess platform is developed.
Molecule-specific process quick to be adjusted.
Optimized cost of goods, CoGs
Reduced usage of single-use consumables, cheap raw materials, fast manufacturing process (up to 6 weeks)
"A unique biotech platform that not only optimizes the efficacy and safety of drug products, but also integrates environmental and economic impacts into every step." Alexandre HILL, CEO
A wide range of applications in the pharmaceutical industry starting with
therapeutic cancer vaccination
IP - Intellectual property
Exclusive rights on the following patents
Publications
Combining fundamental research in plant biology and immunology with program management for pharmaceutical product development, alongside extensive experience in biotech entrepreneurship and finance.
NEPOVIRUS COAT PROTEIN FUSION POLYPEPTIDES AND THEIR USE
Publication N°: WO/2017/042367
Filing date: 09.09.2016
All the know-how of VLP engineering by genetic fusion is protected.
VIRUS-LIKE PARTICLES AND USES THEREOF
Publication N°: WO/2018/167070
Filing date: 13.03.2018
All the know-how of VLP engineering by ligand-based display is protected.
Serendip management team
Four scientists fully dedicated to a mission: harnessing the efficacy and efficiency of plants to serve the pharmaceutical industry and improve human health.
More about us
Support &
funding
Academic R&D collaborations
Incubator and biocluster support
Funding
Training
